Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell ...

Investors in BioNTech SE (Symbol: BNTX) saw new options become available this week, for the January 2025 expiration. One of the key data points that goes into the price an option buyer is willing ...

Here is how BioNTech SE Sponsored ADR (BNTX) and EUROFINS SCIENT (ERFSF) have performed compared to their sector so far this year.

BioNTech (BNTX) is a stock many investors are watching right now. BNTX is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. We should also highlight that BNTX has a P/B ratio of 1.21.

According to data from Benzinga Pro, BNTX has a 52-week high of $125.83 and a 52-week low of $78.02.

The race to develop effective cancer vaccines has entered a new phase, with late-stage trials from companies like Moderna ...

Pfizer Inc. PFE along with BioNTech SE BNTX announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) has rendered a positive opinion ...

BioNTech stock (NASDAQ: BNTX), a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, declined by almost 31% over the last month, considerably underperforming the S&P 500 ...